255 related articles for article (PubMed ID: 9816166)
1. Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins.
Reiter Y; Pastan I
Clin Cancer Res; 1996 Feb; 2(2):245-52. PubMed ID: 9816166
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
[TBL] [Abstract][Full Text] [Related]
3. Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments.
Reiter Y; Brinkmann U; Lee B; Pastan I
Nat Biotechnol; 1996 Oct; 14(10):1239-45. PubMed ID: 9631086
[TBL] [Abstract][Full Text] [Related]
4. Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv.
Reiter Y; Brinkmann U; Webber KO; Jung SH; Lee B; Pastan I
Protein Eng; 1994 May; 7(5):697-704. PubMed ID: 8073039
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin.
Reiter Y; Kreitman RJ; Brinkmann U; Pastan I
Int J Cancer; 1994 Jul; 58(1):142-9. PubMed ID: 8014011
[TBL] [Abstract][Full Text] [Related]
6. Improved stability and yield of Fv targeted superantigen by introducing both linker and disulfide bond into the targeting moiety.
Hao HJ; Jiang YQ; Zheng YL; Ma R; Yu DW
Biochimie; 2005 Aug; 87(8):661-7. PubMed ID: 15927340
[TBL] [Abstract][Full Text] [Related]
7. Disulfide stabilization of antibody Fv: computer predictions and experimental evaluation.
Reiter Y; Brinkmann U; Jung SH; Pastan I; Lee B
Protein Eng; 1995 Dec; 8(12):1323-31. PubMed ID: 8869646
[TBL] [Abstract][Full Text] [Related]
8. Recombinant single-chain and disulfide-stabilized Fv-immunotoxins that cause complete regression of a human colon cancer xenograft in nude mice.
Reiter Y; Wright AF; Tonge DW; Pastan I
Int J Cancer; 1996 Jul; 67(1):113-23. PubMed ID: 8690511
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and antitumor activity of a bivalent disulfide-stabilized Fv immunotoxin with improved antigen binding to erbB2.
Bera TK; Viner J; Brinkmann E; Pastan I
Cancer Res; 1999 Aug; 59(16):4018-22. PubMed ID: 10463601
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
Kreitman RJ; Margulies I; Stetler-Stevenson M; Wang QC; FitzGerald DJ; Pastan I
Clin Cancer Res; 2000 Apr; 6(4):1476-87. PubMed ID: 10778980
[TBL] [Abstract][Full Text] [Related]
11. Improved stability and yield of a Fv-toxin fusion protein by computer design and protein engineering of the Fv.
Chowdhury PS; Vasmatzis G; Beers R; Lee B; Pastan I
J Mol Biol; 1998 Sep; 281(5):917-28. PubMed ID: 9719644
[TBL] [Abstract][Full Text] [Related]
12. Stabilization of a recombinant Fv fragment by base-loop interconnection and V(H)-V(L) permutation.
Brinkmann U; Di Carlo A; Vasmatzis G; Kurochkina N; Beers R; Lee B; Pastan I
J Mol Biol; 1997 Apr; 268(1):107-17. PubMed ID: 9149145
[TBL] [Abstract][Full Text] [Related]
13. Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment.
Reiter Y; Brinkmann U; Jung SH; Lee B; Kasprzyk PG; King CR; Pastan I
J Biol Chem; 1994 Jul; 269(28):18327-31. PubMed ID: 7913461
[TBL] [Abstract][Full Text] [Related]
14. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.
Salvatore G; Beers R; Margulies I; Kreitman RJ; Pastan I
Clin Cancer Res; 2002 Apr; 8(4):995-1002. PubMed ID: 11948105
[TBL] [Abstract][Full Text] [Related]
15. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
Brinkmann U; Reiter Y; Jung SH; Lee B; Pastan I
Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7538-42. PubMed ID: 8356052
[TBL] [Abstract][Full Text] [Related]
16. Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions.
Reiter Y; Brinkmann U; Kreitman RJ; Jung SH; Lee B; Pastan I
Biochemistry; 1994 May; 33(18):5451-9. PubMed ID: 7910034
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity of Antiosteosarcoma Recombinant Immunotoxins Composed of TP-3 Fv Fragments and a Truncated Pseudomonas Exotoxin A.
Onda M; Olafsen T; Tsutsumi Y; Bruland ØS ØS; Pastan I
J Immunother (1991); 2001 Mar; 24(2):144-150. PubMed ID: 11449071
[TBL] [Abstract][Full Text] [Related]
18. Bivalent disulfide-stabilized fragment variable immunotoxin directed against mesotheliomas and ovarian cancer.
Bera TK; Williams-Gould J; Beers R; Chowdhury P; Pastan I
Mol Cancer Ther; 2001 Dec; 1(2):79-84. PubMed ID: 12467225
[TBL] [Abstract][Full Text] [Related]
19. Characterization of B1(Fv)PE38 and B1(dsFv)PE38: single-chain and disulfide-stabilized Fv immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice.
Benhar I; Pastan I
Clin Cancer Res; 1995 Sep; 1(9):1023-9. PubMed ID: 9816075
[TBL] [Abstract][Full Text] [Related]
20. Comparison of recombinant immunotoxins against LeY antigen expressing tumor cells: influence of affinity, size, and stability.
Bera TK; Pastan I
Bioconjug Chem; 1998; 9(6):736-43. PubMed ID: 9815167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]